TENX TENAX THERAPEUTICS, INC.

Nasdaq tenaxthera.com


$ 7.58 $ -0.53 (-7.06 %)    

Wednesday, 15-Oct-2025 18:11:32 EDT
QQQ $ 602.61 $ 4.22 (0.71 %)
DIA $ 463.04 $ 0.00 (0 %)
SPY $ 665.11 $ 2.94 (0.44 %)
TLT $ 90.76 $ -0.20 (-0.22 %)
GLD $ 387.41 $ 6.60 (1.73 %)
$ 6.98
$ 7.46
$ 7.40 x 424
$ 8.16 x 100
$ 6.93 - $ 7.53
$ 3.65 - $ 8.24
113,805
na
31.85M
$ 0.73
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-13-2025 06-30-2025 10-Q
2 05-14-2025 03-31-2025 10-Q
3 03-25-2025 12-31-2024 10-K
4 11-13-2024 09-30-2024 10-Q
5 08-13-2024 06-30-2024 10-Q
6 05-14-2024 03-31-2024 10-Q
7 03-28-2024 12-31-2023 10-K
8 11-13-2023 09-30-2023 10-Q
9 08-14-2023 06-30-2023 10-Q
10 05-15-2023 03-31-2023 10-Q
11 03-31-2023 12-31-2022 10-K
12 11-10-2022 09-30-2022 10-Q
13 08-11-2022 06-30-2022 10-Q
14 05-16-2022 03-31-2022 10-Q
15 03-29-2022 12-31-2021 10-K
16 11-15-2021 09-30-2021 10-Q
17 08-16-2021 06-30-2021 10-Q
18 05-17-2021 03-31-2021 10-Q
19 03-31-2021 12-31-2020 10-K
20 11-16-2020 09-30-2020 10-Q
21 08-14-2020 06-30-2020 10-Q
22 05-15-2020 03-31-2020 10-Q
23 03-30-2020 12-31-2019 10-K
24 11-14-2019 09-30-2019 10-Q
25 08-14-2019 06-30-2019 10-Q
26 05-15-2019 03-31-2019 10-Q
27 04-01-2019 12-31-2018 10-K
28 11-14-2018 09-30-2018 10-Q
29 08-14-2018 06-30-2018 10-Q
30 05-15-2018 03-31-2018 10-Q
31 04-02-2018 12-31-2017 10-K
32 11-09-2017 09-30-2017 10-Q
33 08-09-2017 06-30-2017 10-Q
34 05-10-2017 03-31-2017 10-Q
35 03-16-2017 12-31-2016 10-K
36 11-09-2016 09-30-2016 10-Q
37 08-09-2016 06-30-2016 10-Q
38 05-10-2016 03-31-2016 10-Q
39 12-10-2015 10-31-2015 10-Q
40 09-09-2015 07-31-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 tenax-therapeutics-expands-global-rights-to-develop-and-manufacture-oral-levosimendan-under-amended-agreement-with-orion

On September 3, 2025, Tenax Therapeutics, Inc. (the "Company") and Orion Corporation ("Orion") entered into an ...

 piper-sandler-initiates-coverage-on-tenax-therapeutics-with-overweight-rating-announces-price-target-of-20

Piper Sandler analyst Yasmeen Rahimi initiates coverage on Tenax Therapeutics (NASDAQ:TENX) with a Overweight rating and ann...

 guggenheim-maintains-buy-on-tenax-therapeutics-lowers-price-target-to-14

Guggenheim analyst Seamus Fernandez maintains Tenax Therapeutics (NASDAQ:TENX) with a Buy and lowers the price target from $...

 tenax-therapeutics-q1-eps-028-misses-019-estimate

Tenax Therapeutics (NASDAQ:TENX) reported quarterly losses of $(0.28) per share which missed the analyst consensus estimate of ...

 tenax-therapeutics-q4-2024-gaap-eps-018-beats-042-estimate

Tenax Therapeutics (NASDAQ:TENX) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(...

 tenax-therapeutics-announces-25m-private-placement-with-rtw-investments

Tenax Therapeutics, Inc. (NASDAQ:TENX) (the "Company" or "Tenax Therapeutics"), a Phase 3, development-stage ph...

 tenax-therapeutics-announces-fda-review-completion-of-updated-phase-3-plan-for-tnx-103-expands-level-study-enrollment-to-230-patients-with-over-95-power-level-2-global-study-to-begin-in-2025

Tenax Therapeutics, Inc. (NASDAQ:TENX) ("Tenax Therapeutics" or the "Company"), a Phase 3, development-stage ph...

 tenax-therapeutics-appoints-thomas-a-mcgauley-as-interim-cfo-effective-december-2-2024

- SEC Filing

 tenax-therapeutics-q3-2024-gaap-eps-019-beats-139-estimate-cash-cash-equivalents-and-investments-of-983m-expected-to-provide-a-cash-runway-through-the-end-of-2027

Tenax Therapeutics (NASDAQ:TENX) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(...

 leerink-partners-initiates-coverage-on-tenax-therapeutics-with-outperform-rating-announces-price-target-of-16

Leerink Partners analyst David Risinger initiates coverage on Tenax Therapeutics (NASDAQ:TENX) with a Outperform rating and ...

 guggenheim-initiates-coverage-on-tenax-therapeutics-with-buy-rating-announces-price-target-of-16

Guggenheim analyst Seamus Fernandez initiates coverage on Tenax Therapeutics (NASDAQ:TENX) with a Buy rating and announces P...

 william-blair-initiates-coverage-on-tenax-therapeutics-with-outperform-rating

William Blair analyst Matt Phipps initiates coverage on Tenax Therapeutics (NASDAQ:TENX) with a Outperform rating.

 tenax-therapeutics-q2-2024-adj-eps-183-beats-199-estimate

Tenax Therapeutics (NASDAQ:TENX) reported quarterly losses of $(1.83) per share which beat the analyst consensus estimate of $(...

Core News & Articles
Market-Moving News for August 6th
08/06/2024 12:23:44

LUMN: 58% | Lumen Technologies shares are trading higher after the company announced it secured $5 billion in new business from...

 tenax-therapeutics-secures-100m-in-oversubscribed-private-placement-financing

The private placement was led by new investor BVF Partners LP, with participation from other new investors, including Venrock H...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION